(Press-News.org) ANN ARBOR, Mich. -- The anti-inflammatory class of drugs NSAIDs have shown great promise in preventing cancers including colon, esophagus and skin. However, they can increase the risks of heart attacks, ulcers and rare but potentially life-threatening bleeds.
A new study suggests there may be ways to reduce these dangerous side effects.
Collaborators from the University of Michigan, the National Cancer Institute and the University of Alabama looked at naproxen, which is known to have a lower cardiovascular risk than other NSAIDs. Naproxen, like most NSAIDs and aspirin, does increase the risk for gastric ulcers or bleeding. Here, the researchers used the proton pump inhibitor omeprazole, a commonly used acid inhibitor, in combination with naproxen and tested its effects on cancer prevention in a rat model of bladder cancer.
They found that naproxen reduced the incidence of bladder cancer by 75 percent in rats. Omeprazole by itself did not affect the development of cancer but it also did not interfere with the effect of naproxen at preventing tumors. The rats who received naproxen alone or naproxen with omeprazole developed cancer at similarly low rates, while all rats receiving omeprazole alone or no treatment developed bladder cancer.
Clinical data in humans has previously shown combining omeprazole plus naproxen reduced gastric toxicity roughly 70 percent.
The authors also found that intermittent dosing with naproxen (three weeks on the drugs, followed by three weeks off) was highly effective and likely to reduce gastric toxicity. However, it does not have the clear clinical data supporting reduced gastric toxicity associated with naproxen and omeprazole.
"Our study shows that naproxen works just as well with a proton pump inhibitor as without. This provides proof of principle that this could be a valuable cancer prevention strategy and one hopes it can advance quickly to a clinical trial for those at high risk of colon, esophageal, squamous cell skin cancer or potentially other cancers," says lead study author Ronald A. Lubet, Ph.D., a scientist with the Chemopreventive Agent Development Research Group at the National Cancer Institute.
"The ability to reduce the gastric effects of NSAIDs adds another element to ongoing discussions of whether the NSAID aspirin might be applicable to prevention studies in a more general population, since the gastric toxicity of even low-dose aspirin has been considered a hurdle," he adds.
The current study is published in the American Association for Cancer Research journal Cancer Prevention Research.
"Naproxen is a great candidate for chemoprevention. It comes with a risk of gastrointestinal side effects, but if you can mitigate that with a co-prescription, it's possibly an ideal chemoprevention drug," says study author James Scheiman, M.D., professor of gastroenterology at the University of Michigan Medical School. Scheiman has studied the use of NSAIDs in chemoprevention and has co-authored guidelines on the gastrointestinal risks of aspirin and NSAIDs.
The combination of naproxen plus a proton pump inhibitor is already used in people with arthritis. Naproxen and omeprazole are both available over the counter.
The authors hope to plan a clinical trial to look at naproxen plus omeprazole in people at high risk of colon or other cancers. This is not currently available. Patients seeking more information about cancer prevention can call the U-M Cancer AnswerLine at 800-865-1125.
INFORMATION:
Additional authors: Ann Bode, Hormel Institute at the University of Minnesota; Jonathan White, Midwest Research Institute in Kansas City, Mo.; Lori Minasian, Daniel L. Boring and Vernon E. Steele, NCI; M. Margaret Juliana and Clinton J. Grubbs, University of Alabama at Birmingham
Funding: National Cancer Institute grant N01-CN43301
Disclosure: Scheiman has served as a paid expert to pharmaceutical companies that market NSAIDs and proton pump inhibitors.
Reference: Cancer Prevention Research, "Naproxen Prevention of Urinary Bladder Cancer," published online March 11, 2015
Resources:
U-M Cancer AnswerLine, 800-865-1125
U-M Comprehensive Cancer Center, http://www.mcancer.org
Clinical trials at U-M, http://www.mcancer.org/clinicaltrials
mCancerTalk blog, http://uofmhealthblogs.org/cancer
An Antarctic octopus that lives in ice-cold water uses an unique strategy to transport oxygen in its blood, according to research published in Frontiers in Zoology. The study suggests that the octopus's specialized blood pigments could help to make it more resilient to climate change than Antarctic fish and other species of octopus.
The Antarctic Ocean hosts rich and diverse fauna despite inhospitable temperatures close to freezing. While it can be hard to deliver oxygen to tissues in the cold due to lower oxygen diffusion and increased blood viscosity, ice-cold waters ...
Studying the intricate fractal patterns on the surface of cells could give researchers a new insight into the physical nature of cancer, and provide new ways of preventing the disease from developing.
This is according to scientists in the US who have, for the first time, shown how physical fractal patterns emerge on the surface of human cancer cells at a specific point of progression towards cancer.
Publishing their results today, 11 March, in the Institute of Physics and Germany Physical Society's New Journal of Physics, they found that the distinctive repeating fractal ...
Voices in people's heads are far more varied and complex than previously thought, according to new research by Durham and Stanford universities, published in The Lancet Psychiatry today.
One of the largest and most detailed studies to date on the experience of auditory hallucinations, commonly referred to as voice hearing, found that the majority of voice-hearers hear multiple voices with distinct character-like qualities, with many also experiencing physical effects on their bodies.
The study also confirmed that both people with and without psychiatric diagnoses hear ...
During pregnancy, the mother supplies the fetus with nutrients and oxygen via the placenta. If placental development is impaired, this may lead to growth disorders of the embryo or to life-threatening diseases of the mother such as preeclampsia, a serious condition involving high blood pressure and increased urinary protein excretion. Now, Dr. Katharina Walentin and Professor Kai Schmidt-Ott of the Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch have discovered a new molecular signaling pathway which regulates the development of the placenta. Perturbations ...
In a study published in The Lancet on March 10, researchers from Brigham and Women's Hospital (BWH) report that patients with a genetic sensitivity to warfarin - the most widely used anticoagulant for preventing blood clots - have higher rates of bleeding during the first several months of treatment and benefited from treatment with a different anticoagulant drug. The analyses from the TIMI Study Group, suggest that using genetics to identify patients who are most at risk of bleeding, and tailoring treatment accordingly, could offer important safety benefits, particularly ...
VANCOUVER, Wash.--Washington State University researchers have found a mechanism in the brain that facilitates the pathologically powerful role of memory in drug addiction. Their discovery opens a new area of research for targeted therapy that would alter or disable the mechanism and make drug addiction less compulsive.
Turning off the mechanism is "diminishing the emotional impact or the emotional content of the memory, so it decreases the motivation to relapse," said Barbara Sorg, a professor of neuroscience at Washington State University, Vancouver. Her findings appear ...
Scientists from the U.S. Department of Energy's Lawrence Berkeley National Laboratory (Berkeley Lab) have uncovered new clues about the risk of cancer from low-dose radiation, which in this research they define as equivalent to 100 millisieverts or roughly the dose received from ten full-body CT scans.
They studied mice and found their risk of mammary cancer from low-dose radiation depends a great deal on their genetic makeup. They also learned key details about how genes and the cells immediately surrounding a tumor (also called the tumor microenvironment) affect cancer ...
La Jolla, Calif., March 9, 2015 - Researchers at Sanford-Burnham Medical Research Institute (Sanford-Burnham) have discovered a mechanism that explains why some breast cancer tumors respond to specific chemotherapies and others do not. The findings highlight the level of glutamine, an essential nutrient for cancer development, as a determinant of breast cancer response to select anticancer therapies, and identify a marker associated with glutamine uptake, for potential prognosis and stratification of breast cancer therapy.
"Our study indicates that a protein called RNF5 ...
McGill researchers have discovered, for the first time, the importance of a key epigenetic regulator in the development of the hippocampus, a part of the brain associated with learning, memory and neural stem cells. Epigenetic regulators change the way specific genes function without altering their DNA sequence. By working with mutant mice as models, the research team, led by Prof. Xiang-Jiao Yang, of McGill's Goodman Cancer Center & Department of Medicine, McGill University Health Center, was able to link the importance of a specific epigenetic regulator known as BRPF1 ...
The combination of stress and heavy depression can significantly increase heart patient's risk of death or heart attack, according to new research in Circulation: Cardiovascular Quality and Outcomes, an American Heart Association journal.
The study examined the effect of high stress levels and high depressive symptoms among nearly 5,000 heart patients. Researchers concluded that risk is amplified when both conditions are present, thus validating the concept of a "psychosocial perfect storm."
"The increase in risk accompanying high stress and high depressive symptoms ...
